TrialCalcified tissue international2014

Increased bone mineral density with monthly intravenous ibandronate contributes to fracture risk reduction in patients with primary osteoporosis: three-year analysis of the MOVER study.

Hiroshi Hagino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.